Biodesix Inc

Five biotech stocks profiled by RTTNews reached new 52-week highs last week, with gains ranging from 105% to 235% since their respective publication dates. Twist Bioscience soared 235% to a high of $104.23, driven by strong revenue and an upcoming quarterly report. Biodesix climbed 124% to $23.34 following better-than-expected results, raised guidance, and positive clinical validation data. Mirum Pharmaceuticals rose 133% to $124.44 on consistent revenue growth, the Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat. Candel Therapeutics advanced 108% to $9.99 after extended survival data for Aglatimagene and a commercialization agreement with EVERSANA. Indivior Pharmaceuticals gained 105% to $42.81, supported by solid earnings, upbeat guidance, and real-world evidence favoring Sublocade.

Biodesix shares ended the last trading session 10.5% higher at $16.81 on heavy volume. The jump followed Canaccord Genuity raising its price target on the company from $22.00 to $27.00 while maintaining a Buy rating. Biodesix reported strong progress in the first quarter of 2026 across its three objectives of driving top-line growth, improving operational efficiency and leverage, and advancing its pipeline. The company is expected to post a quarterly loss of $0.85 per share, a 46.9% improvement year-over-year, on revenues of $26.1 million, up 30.4% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 4% higher over the last 30 days, and the stock carries a Zacks Rank of 2, or Buy.